Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBUPROFEN AND FAMOTIDINE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis,Management of ankylosing spondylitis,Dysmenorrhea,Mild to moderate pain,Reduction of fever,Off-label: Migraine, gout, acute musculoskeletal pain
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (Cr Cl <10 m L/min).
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Famotidine is minimally metabolized in the liver (30-35%) via oxidative pathways; the remainder is excreted unchanged in urine.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Ibuprofen: >99% bound to albumin (mostly). Famotidine: 15-20% bound to plasma proteins (albumin).
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding and limited tissue distribution). Famotidine: 1.1-1.4 L/kg (suggests extensive extravascular distribution).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Ibuprofen: Oral: 80-100% (well absorbed with food causing slight delay). Famotidine: Oral: 40-50% (first-pass metabolism; reduced with food).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Contraindicated if Cr Cl < 30 m L/min. For Cr Cl 30-49 m L/min, reduce famotidine dose by 50% (not possible with fixed combination; use alternative therapy).
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No specific dose adjustment for Child-Pugh A or B; avoid in severe hepatic impairment (Child-Pugh C) due to ibuprofen component.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not established for combination; ibuprofen 5-10 mg/kg/dose (max 400 mg) q6-8h as separate agent; famotidine 0.5 mg/kg/dose (max 20 mg) q12h for pediatric use.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at lowest effective dose; monitor renal function; avoid if Cr Cl < 30 m L/min; increased risk of GI bleeding and renal impairment.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events. Gastrointestinal risk: Serious GI adverse events including bleeding, ulceration, and perforation. Renal toxicity: Monitor renal function. Hepatic effects: Elevation of liver enzymes. Anaphylactoid reactions: Bronchospasm in aspirin-sensitive asthma. Hypertension: Can worsen blood pressure control. Fluid retention and edema.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
History of allergic reaction to ibuprofen, famotidine, or any other NSAID. History of aspirin-sensitive asthma. Coronary artery bypass graft (CABG) surgery. Active peptic ulcer disease or GI bleeding. Advanced renal disease. Pregnancy at 30 weeks gestation and later (risk of premature closure of ductus arteriosus).
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid alcohol; increases GI bleeding risk. No other significant food interactions. Take with food or milk to reduce gastric irritation.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low risk, but limited data. Second trimester: Ibuprofen use is linked to fetal renal dysfunction and oligohydramnios; famotidine appears safe. Third trimester: Ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension; famotidine has no known fetal risks.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Ibuprofen: Excretion into breast milk is low (M/P ratio 0.007-0.24); considered compatible with breastfeeding. Famotidine: Excreted in breast milk (M/P ratio approximately 0.25-0.71); infant exposure is low; generally acceptable with caution. Combined use: Limited data; monitor infant for gastrointestinal effects.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Ibuprofen: No standard dose adjustment; avoid in third trimester. Famotidine: No dose adjustment required. Combined product: Avoid in third trimester; use lowest effective dose and shortest duration in first/second trimester.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Ibuprofen and famotidine combination tablet (Duexis) is used for osteoarthritis and rheumatoid arthritis to reduce GI ulcer risk. Do not exceed 800 mg ibuprofen per dose or 3200 mg per day. Famotidine component provides gastric protection; additional acid suppression not needed. Avoid in advanced renal disease, active GI bleeding, or COX-2 inhibitor allergy. Monitor renal function, BP, and signs of GI bleeding. Dual COX/5-LOX inhibition by ibuprofen raises cardiovascular thrombotic risk; use lowest effective dose.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take with food or milk to reduce stomach upset.,Do not take more than 3 tablets per day (each tablet contains 800 mg ibuprofen).,May cause drowsiness or dizziness; avoid driving if affected.,Report black/tarry stools, vomiting blood, chest pain, or leg swelling immediately.,Avoid alcohol and other NSAIDs (e.g., aspirin, naproxen) while taking this medication.,Inform all healthcare providers you are taking this drug, especially before surgery.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBUPROFEN AND FAMOTIDINE vs ACTIQ, answered by our medical review team.
IBUPROFEN AND FAMOTIDINE is a NSAID that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBUPROFEN AND FAMOTIDINE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBUPROFEN AND FAMOTIDINE is: One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBUPROFEN AND FAMOTIDINE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBUPROFEN AND FAMOTIDINE is classified as Category D/X. First trimester: Ibuprofen is associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Famotidine is generally considered low ri. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.